{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-7.45","upperLimit":"-3.52","value":"-5.48"},{"groupId":"OG001","lowerLimit":"-6.74","upperLimit":"-2.69","value":"-4.72"},{"groupId":"OG002","lowerLimit":"-9.33","upperLimit":"-1.98","value":"-5.65"},{"groupId":"OG003","lowerLimit":"-9.58","upperLimit":"-2.00","value":"-5.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"247"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"63"}],"units":"Participants"}],"title":"Fatigue, First 9 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-6.35","upperLimit":"-1.91","value":"-4.13"},{"groupId":"OG001","lowerLimit":"-8.02","upperLimit":"-3.54","value":"-5.78"},{"groupId":"OG002","lowerLimit":"-6.05","upperLimit":"2.58","value":"-1.73"},{"groupId":"OG003","lowerLimit":"-11.30","upperLimit":"-2.33","value":"-6.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"236"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"63"}],"units":"Participants"}],"title":"Fatigue, week 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-7.31","upperLimit":"-2.91","value":"-5.11"},{"groupId":"OG001","lowerLimit":"-8.81","upperLimit":"-4.23","value":"-6.52"},{"groupId":"OG002","lowerLimit":"-9.51","upperLimit":"-1.29","value":"-5.40"},{"groupId":"OG003","lowerLimit":"-10.61","upperLimit":"-2.12","value":"-6.36"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"237"},{"groupId":"OG001","value":"210"},{"groupId":"OG002","value":"65"},{"groupId":"OG003","value":"61"}],"units":"Participants"}],"title":"Fatigue, week 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-9.21","upperLimit":"-4.44","value":"-6.83"},{"groupId":"OG001","lowerLimit":"-8.23","upperLimit":"-3.31","value":"-5.77"},{"groupId":"OG002","lowerLimit":"-11.26","upperLimit":"-2.03","value":"-6.64"},{"groupId":"OG003","lowerLimit":"-12.61","upperLimit":"-3.19","value":"-7.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"214"},{"groupId":"OG002","value":"61"},{"groupId":"OG003","value":"60"}],"units":"Participants"}],"title":"Fatigue, week 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-8.75","upperLimit":"-3.61","value":"-6.18"},{"groupId":"OG001","lowerLimit":"-7.63","upperLimit":"-2.28","value":"-4.96"},{"groupId":"OG002","lowerLimit":"-13.30","upperLimit":"-4.54","value":"-8.92"},{"groupId":"OG003","lowerLimit":"-8.32","upperLimit":"0.58","value":"-3.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"195"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"57"}],"units":"Participants"}],"title":"Fatigue, week 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-7.94","upperLimit":"-2.43","value":"-5.19"},{"groupId":"OG001","lowerLimit":"-6.16","upperLimit":"-0.35","value":"-3.26"},{"groupId":"OG002","lowerLimit":"-9.53","upperLimit":"0.68","value":"-4.43"},{"groupId":"OG003","lowerLimit":"-11.53","upperLimit":"-1.10","value":"-6.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"178"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"56"}],"units":"Participants"}],"title":"Fatigue, week 30"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-8.31","upperLimit":"-2.63","value":"-5.47"},{"groupId":"OG001","lowerLimit":"-2.00","upperLimit":"1.04","value":"-2.00"},{"groupId":"OG002","lowerLimit":"-12.38","upperLimit":"-1.19","value":"-6.78"},{"groupId":"OG003","lowerLimit":"-9.28","upperLimit":"2.36","value":"-3.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"158"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"50"}],"units":"Participants"}],"title":"Fatigue, week 36"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-8.39","upperLimit":"-3.90","value":"-6.15"},{"groupId":"OG001","lowerLimit":"-7.96","upperLimit":"-3.32","value":"-5.64"},{"groupId":"OG002","lowerLimit":"-2.78","upperLimit":"5.14","value":"1.18"},{"groupId":"OG003","lowerLimit":"-5.80","upperLimit":"2.34","value":"-1.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"247"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"63"}],"units":"Participants"}],"title":"Appetite Loss, First 9 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-7.36","upperLimit":"-1.72","value":"-4.54"},{"groupId":"OG001","lowerLimit":"-8.52","upperLimit":"-2.83","value":"-5.67"},{"groupId":"OG002","lowerLimit":"-1.60","upperLimit":"8.01","value":"3.20"},{"groupId":"OG003","lowerLimit":"-11.26","upperLimit":"-1.27","value":"-6.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"236"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"63"}],"units":"Participants"}],"title":"Appetite Loss, week 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-9.43","upperLimit":"-3.62","value":"-6.52"},{"groupId":"OG001","lowerLimit":"-9.98","upperLimit":"-3.91","value":"-6.95"},{"groupId":"OG002","lowerLimit":"-3.23","upperLimit":"6.39","value":"1.58"},{"groupId":"OG003","lowerLimit":"-6.41","upperLimit":"3.53","value":"-1.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"237"},{"groupId":"OG001","value":"210"},{"groupId":"OG002","value":"65"},{"groupId":"OG003","value":"61"}],"units":"Participants"}],"title":"Appetite Loss, week 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-10.09","upperLimit":"-4.45","value":"-7.27"},{"groupId":"OG001","lowerLimit":"-9.75","upperLimit":"-3.92","value":"-6.84"},{"groupId":"OG002","lowerLimit":"-4.38","upperLimit":"7.22","value":"1.42"},{"groupId":"OG003","lowerLimit":"-10.35","upperLimit":"1.48","value":"-4.43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"214"},{"groupId":"OG002","value":"61"},{"groupId":"OG003","value":"60"}],"units":"Participants"}],"title":"Appetite Loss, week 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-10.27","upperLimit":"-4.01","value":"-7.14"},{"groupId":"OG001","lowerLimit":"-8.35","upperLimit":"-1.81","value":"-5.08"},{"groupId":"OG002","lowerLimit":"-7.74","upperLimit":"3.22","value":"-2.26"},{"groupId":"OG003","lowerLimit":"-5.29","upperLimit":"5.78","value":"0.24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"195"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"57"}],"units":"Participants"}],"title":"Appetite Loss, week 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-7.74","upperLimit":"-1.26","value":"-4.50"},{"groupId":"OG001","lowerLimit":"-7.60","upperLimit":"-0.74","value":"-4.17"},{"groupId":"OG002","lowerLimit":"-3.28","upperLimit":"7.65","value":"2.19"},{"groupId":"OG003","lowerLimit":"-7.36","upperLimit":"3.70","value":"-1.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"178"},{"groupId":"OG002","value":"57"},{"groupId":"OG003","value":"56"}],"units":"Participants"}],"title":"Appetite Loss, week 30"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-10.00","upperLimit":"-3.81","value":"-6.90"},{"groupId":"OG001","lowerLimit":"-8.49","upperLimit":"-1.81","value":"-5.15"},{"groupId":"OG002","lowerLimit":"-5.28","upperLimit":"7.24","value":"0.98"},{"groupId":"OG003","lowerLimit":"-3.15","upperLimit":"9.86","value":"3.36"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"158"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"50"}],"units":"Participants"}],"title":"Appetite Loss, week 36"}],"denoms":[{"counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"277"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"65"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 cancer-specific questionnaire consisted of 30 questions, combined to produce 5 functional scales, 3 symptom scales, 6 individual items, and a global measure of health status/QoL. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, the functional scales, and the global health status/QoL scale in the EORTC QLQ-C30. Higher scores on the global health status and functioning scales indicated better health status/function. Higher scores on the symptoms scales indicated greater symptom burden. The analysis was performed using a Mixed-effects model for repeated measures analysis on the change from baseline in PRO symptom score at each visit up to 9 months (281 days), including participants, treatment, visit and treatment by visit interaction as explanatory variables, the baseline PRO score as a covariate along with the baseline PRO score by visit interaction, using an unstructured covariance structure.","dispersionType":"95% Confidence Interval","groups":[{"description":"Randomized participants received Osimertinib 80 mg orally once daily (QD)","id":"OG000","title":"Osimertinib 80 mg (Global Cohort)"},{"description":"Randomized participant received Standard of care (SoC) Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Participants received gefitinib 250 mg orally QD or erlotinib 150 mg orally QD.","id":"OG001","title":"SoC EGFR-TKI (Global Cohort)"},{"description":"Randomized participants received Osimertinib 80 mg orally once daily (QD)","id":"OG002","title":"Osimertinib 80 mg (China Cohort)"},{"description":"Randomized participant received Standard of care (SoC) Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFRTKI). Participants received gefitinib 250 mg orally QD or erlotinib 150 mg orally QD.","id":"OG003","title":"SoC EGFR-TKI (China Cohort)"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The full analysis set (FAS) and China-only FAS. FAS included all randomized participants prior to the end of global recruitment. The China-only FAS included all China participants randomized in mainland-China as part of the global study and all additional China participants recruited in mainland China after global recruitment was completed.","reportingStatus":"POSTED","timeFrame":"Questionnaires completed at baseline, first 9 months, and at week 6, 12, 18, 24, 30, and 36.","title":"Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30)","type":"SECONDARY","unitOfMeasure":"Unit on scale"}